metadoxine has been researched along with naltrexone in 2 studies
Studies (metadoxine) | Trials (metadoxine) | Recent Studies (post-2010) (metadoxine) | Studies (naltrexone) | Trials (naltrexone) | Recent Studies (post-2010) (naltrexone) |
---|---|---|---|---|---|
60 | 18 | 12 | 8,745 | 1,228 | 2,642 |
Protein | Taxonomy | metadoxine (IC50) | naltrexone (IC50) |
---|---|---|---|
Cytochrome P450 2D6 | Homo sapiens (human) | 1 | |
Delta-type opioid receptor | Mus musculus (house mouse) | 0.0051 | |
Delta-type opioid receptor | Rattus norvegicus (Norway rat) | 0.0063 | |
Kappa-type opioid receptor | Mus musculus (house mouse) | 0.006 | |
Mu-type opioid receptor | Rattus norvegicus (Norway rat) | 0.0005 | |
Kappa-type opioid receptor | Rattus norvegicus (Norway rat) | 0.0005 | |
Mu-type opioid receptor | Homo sapiens (human) | 0.006 | |
Delta-type opioid receptor | Homo sapiens (human) | 0.0319 | |
Kappa-type opioid receptor | Cavia porcellus (domestic guinea pig) | 0.0093 | |
Kappa-type opioid receptor | Homo sapiens (human) | 0.0377 | |
Mu-type opioid receptor | Mus musculus (house mouse) | 0.0076 | |
Mu-type opioid receptor | Cavia porcellus (domestic guinea pig) | 0.0004 |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 1 (50.00) | 29.6817 |
2010's | 1 (50.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Pár, A | 1 |
Goh, ET; Morgan, MY | 1 |
2 review(s) available for metadoxine and naltrexone
Article | Year |
---|---|
[Treatment of alcoholic liver diseases. Abstinence, nutritional support, drug therapy, liver transplantation].
Topics: Alcohol Deterrents; Antioxidants; Drug Combinations; Fatty Liver, Alcoholic; Hormones; Humans; Liver; Liver Cirrhosis, Alcoholic; Liver Diseases, Alcoholic; Liver Transplantation; Naltrexone; Narcotic Antagonists; Nutritional Support; Protective Agents; Pyridoxine; Pyrrolidonecarboxylic Acid; Silymarin | 2000 |
Review article: pharmacotherapy for alcohol dependence - the why, the what and the wherefore.
Topics: Acamprosate; Alcohol Deterrents; Alcoholism; Baclofen; Disulfiram; Drug Combinations; Fructose; Humans; Naltrexone; Polymorphism, Single Nucleotide; Pyridoxine; Pyrrolidonecarboxylic Acid; Taurine; Topiramate; Treatment Outcome | 2017 |